Plasmodium vivax malaria vaccine development

Molecular Immunology

Volumn 38, Issue 6, 2001, Pages 443-455

  Arévalo Herrera, Myriam ^a   Herrera, Sócrates ^a  

^a UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Malaria vaccine; Monkey model; Plasmodium vivax

Indexed keywords

ANTIGEN P24; BINDING PROTEIN; CD8 ANTIGEN; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; ERYTHROCYTE ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALARIA VACCINE; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 1; NITRIC OXIDE SYNTHASE; PROTEIN P15; SPOROZOITE SURFACE PROTEIN 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANOPHELES; APICAL MEMBRANE; B LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA; MONKEY; NONHUMAN; PLASMODIUM VIVAX; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIATION ATTENUATION; REVIEW; SPOROZOITE; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, PROTOZOAN; CARRIER PROTEINS; HAPLORHINI; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE;

ANOPHELES ALBIMANUS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 0035652351     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(01)00080-3     Document Type: Review

References (149)

1. Plasmodium vivax polymorphs and Plasmodium falciparum circumsporozoite proteins in Anopheles (Diptera: Culicidae) from Belize, Central America
2. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria
3. Humoral immune responses against Plasmodium vivax MSP1 in human living in a malaria endemic area in Flores, Indonesia
4. Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro
5. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys
6. Identification of HLA-A2 restricted CD8+ T-lymphocytes response to Plasmodium vivax circumsporozoite protein in naturally exposed individuals
7. Circumsporozoite protein of Plasmodium vivax: Gene cloning and characterization of the immunodominant epitope
8. Antigenic diversity in Thai Plasmodium vivax circumsporozoite proteins
9. Plasmodium vivax: A glimpse into the unique and shared biology of the merozoite
10. Plasmodium vivax, P. cynomolgi, and P. knowlesi: Identification of homologue proteins associated with the surface of merozoites
11. Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides
12. Characteristics of natural antibody responses to the circumsporozoite protein of Plasmodium vivax
13. Characterization of naturally acquired antibodies to the non-repetitive flanking regions of the circumsporozoite protein of Plasmodium falciparum
14. The population dynamics in mosquitoes and humans of two Plasmodium vivax polymorphs distinguished by different circumsporozoite protein repeat regions
15. Malaria transmission-blocking vaccines - How can their development be supported?
16. The malaria genome project: From sequence to functional
17. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites
18. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence
19. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 Å resolution, a highly protective malaria vaccine candidate
20. Molecular insights into receptors used by malaria parasites for erythrocyte invasions
21. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites
22. Immunity of falciparum and vivax malaria induced by irradiated sporozoites: A review of the University of Maryland studies, 1971-75
23. Specificity of protection of man immunized against sporozoite-induced falciparum malaria
24. Immunization of man against sporozoite-induced falciparum malaria
25. Antibody-induced ultrastructural changes of malarial sporozoites
26. Widespread reactivity of human sera with a variant repeat of the circumsporozoite protein of Plasmodium vivax
27. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile
28. Testing the efficacy of a recombinant merozoite surface protein MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys
29. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaraia parasite Plasmodium falciparum
30. Vaccination trials in rhesus monkeys with a minor, invariant Plasmodium knowlesi 66 kDa antigen
31. Peptide-primed CD4+ cells and malaria sporozoites
32. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species
33. The complexity of protective immunity against liver-stage malaria
34. DNA-based vaccine against malaria: Status and promise of the multi-stage malaria DNA vaccine operation
35. Immunity to liver stages
36. DNA cloning of Plasmodium falciparum circumsporozoite gene: Amino acid sequence of repetitive epitope
37. Malaria vaccine development: Current status
38. Differential expression of HLA-A*02 subtypes in Colombian Blacks and Mestizos
39. Antibody response to the circumsporozoite protein of Plasmodium vivax in naturally infected humans
40. Prevalence of antibody to the variant repeat of the circumsporozoite protein of Plasmodium vivax in Peru
41. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes
42. Plasmodium vivax merozoite surface protein-3 contains coiled motifs in an alanine-rich central domain
43. Plasmodium vivax merozoite surface proteins-3 beta and -3 gamma share structural similarities with P. vivax merozoite surface protein-3 alpha and define a new gene family
44. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
45. Identification of a T-cell epitope on the circumsporozoite protein of Plasmodium vivax
46. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax
47. HLA-A*0201 restricted CD8+ T-lymphocyte response to malaria: Identification of new Plasmodium falciparum epitopes by IFN-γ ELISPOT
48. Variant of the Plasmodium vivax circumsporozoite protein (VK210 & VK247) in Colombian isolates
49. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule
50. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice
51. Human T cell recognition of polymorphic epitopes form malaria circumsporozoite protein
52. Overview of malaria control in the Americas
53. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: Correlation of serum gamma interferon levels with protection
54. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein
55. Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c mice
56. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys
57. Successful immunization of humans with irradiated malaria sporozoites: Humoral and cellular responses of the protected individuals
58. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes
59. Malaria vaccine-targeting infected hepatocytes
60. Attacking the infected hepatocyte
61. Preventing merozoite invasion of erythrocyte
62. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells an in vitro assay of protective antibodies
63. Malaria vaccine development: Status report
64. Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens
65. Immunogenicity of Plasmodium falciparum sexual stage antigens: Implications for the design of a transmission blocking vaccine
66. Transmission-Blocking Vaccine
67. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains
68. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein
69. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: Strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2
70. Inhibition of malaria parasite development in mosquitoes by anti-mosquito-midgut antibodies
71. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax
72. The analysis of circumsporozoite-protein gene sequences from South Korean isolates of Plasmodium vivax
73. The Plasmodium cynomolgy merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species
74. Immunogenicity of synthetic peptides corresponding to the non-repeat regions of the Plasmodium falciparum circumsporozoite protein
75. A synthetic malaria vaccine elicits a potent CD8+ and CD4+ lymphocyte immune response in humans. Implication for vaccination strategies
76. Distribution of Plasmodium vivax variants (VK210, VK247 and P. vivax-like) in three endemic areas of the Amazon region of Brazil and their correlation with chloroquine treatment
77. Presence of antibodies to a heterologous circumsporozoite protein of Plasmodium vivax (VK247) in south-eastern Bangladesh
78. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein
79. Sequence variation in the circumsporozoite protein gene of Plasmodium vivax appears to be regionally biased
80. The passive transfer of human malarial immunity
81. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans
82. The neglected burden of Plasmodium vivax malaria
83. Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village
84. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein
85. Malaria vaccine: Immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity
86. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1
87. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes
88. T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages
89. Antibodies to sporozoites: Their frequent occurrence in individuals living in an area of hyperendemic malaria
90. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax
91. T cell epitopes of the circumsporozoite protein of Plasmodium vivax. Recognition by lymphocytes of a sporozoite-immunized chimpanzee
92. Pre-erythrocytic malaria vaccine: Mechanisms of protective immunity and human vaccine trials
93. Differential localization of full-length and processed forms of PF83/AMA-1, and apical membrane antigen of Plasmodium falciparum merozoites
94. TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6
95. Universally immunogenic T cell epitope: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
96. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primete model for human Plasmodium vivax malaria
97. Inhibitory activity of IL-6 on malaria hepatic stages
98. IL-6 induced by IL-1 inhibits malaria pre-erythrocytic stages but its secretion is down-regulated by the parasite
99. An antitoxic vaccine for malaria?
100. Interallelic recombinant in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates
101. Polymorphism in the circumsporozoite protein of the human malaria parasite Plasmodium vivax
102. Antibodies to epitopes on merozoite and sporozoite surface antigens as serologic markers of malaria transmission: Studies at a site in the dry zone of Sri Lanka
103. Two Plasmodium falciparum genes express merozoite proteins that are related to Plasmodium vivax and Plasmodium yoelii adhesive proteins involved in host selection and invasion
104. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: Evidence that localization of peptide-specific CTLs is crucial for protection against malaria
105. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-1) or perforin-mediated cytotoxicity
106. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria
107. Cloning and expression of the thrombospondin related adhesive protein gene of Plasmodium berghei
108. Characterization of Plasmodium falciparum sporozoite surface protein
109. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens
110. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein
111. Plasmodium falciparum CS C-terminal fragment: Preclinical evaluation and phase I clinical studies
112. Antigenic analysis of the repeat domain of the circumsporozoite protein of Plasmodium vivax
113. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
114. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax
115. Parasitological and clinical response to immunoglobulin administration in P. falciparum malaria
116. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites
117. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
118. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites
119. Naturally acquired CD8+ cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein
120. Interleukin 12 induction of interferon gamma-dependent protection against malaria
121. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: Involvement of interferon gamma and CD8+ T cells
122. Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum
123. Biochemical, biophysical and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein
124. Preventing sporozoite invasion of hepatocytes
125. Acquired immune response to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria
126. Thrombospondin-related adhesive protein (TRAP) of Plasmodium berghei and motility
127. The Duffy blood group and resistance to Plasmodium vivax in Honduras
128. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies
129. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTSS Malaria Vaccine Evaluation Group
130. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in Aotus challenge trial
131. TRAP is necessary for gliding motility and infectivity of sporozoites
132. Chimpanzees and supporting models in the study of malaria pre-erythrocytic stages
133. Natural variation within the principal adhesion domain of the Plasmodium vivax Duffy binding protein
134. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates
135. CD4+ cytolytic T cell clone confers protection against murine malaria
136. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination
137. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites
138. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes
139. The dynamics of drug resistance in Plasmodium falciparum
140. Drug resistant Plasmodium vivax malaria
141. Vector resistance to pesticides
142. World malaria situation in 1994. Part I. Population at risk
143. Field evaluation of enzyme linked immunosorbent assays for Plasmodium falciparum and Plasmodium vivax sporozoite in mosquitoes (Diptera: Culicidae) from Papua New Guinea
144. Prevalence of antibody to heterologous circumsporozoite protein of Plasmodium vivax in Thailand
145. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2